Syntaxin4-Munc18c Interaction Promotes Breast Tumor Invasion and Metastasis by Regulating MT1-MMP Trafficking

Scientists observed that expression of a construct derived from the N-terminus of Stx4, which interfered with Stx4-Munc18c interaction, led to perturbed trafficking of MT1-MMP, and reduced invadopodium-based invasion in vitro, in models of TNBC.
[Molecular Cancer Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull Article
Bookmark

No account yet? Register

Share

Adipose Derived Mesenchymal Stem Cell Secretome Formulation as a Biotherapeutic to Inhibit Growth of Drug Resistant Triple Negative Breast Cancer

Researchers developed a protocol for processing human adipose derived MSC secretome formulation of varying concentration. Its molecular composition was evaluated, and its effectiveness in vitro using breast cancer cell lines.
[Scientific Reports]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Microfluidic Organ-on-Chip System for Multi-Analyte Monitoring of Metabolites in 3D Cell Cultures

Investigators developed a microfluidic organ-on-chip platform for matrix-based, heterogeneous 3D cultures with fully integrated electrochemical chemo- and biosensor arrays for the energy metabolites oxygen, lactate, and glucose.
[Lab On A Chip]
[zotpress userid=” items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

MLK4 Regulates DNA Damage Response and Promotes Triple-Negative Breast Cancer Chemoresistance

Investigators demonstrated that MLK4 promoted TNBC chemoresistance by regulating the pro-survival response to DNA-damaging therapies and identified a novel function of MLK4 in the regulation of DNA damage response signaling.
[Cell Death & Disease]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

G1 Therapeutics Initiates Phase II Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment

G1 Therapeutics, Inc. announced that the company has initiated a Phase II, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer designed to further investigate the role of trilaciclib in modulating the anti-tumor immune response.
[G1 Therapeutics, Inc.]
[zotpress userid=’7992332′ items=’DDDDDDDD’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Drug-Dependent Morphological Transitions in Spherical and Worm-Like Polymeric Micelles Define Stability and Pharmacological Performance of Micellar Drugs

It was observed that poly(2-oxazoline)-based polymeric micelles could be elongated over time from a spherical structure to worm-like structure, with elongation influenced by several conditions, including the amount and type of drug loaded into the micelles.
[Small]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

lncRNA Prostate Cancer-Associated Transcript 18 Upregulates Activating Transcription Factor 7 to Prevent Metastasis of Triple-Negative Breast Cancer via Sponging miR-103a-3p

Prostate cancer-associated transcript 18 (PCAT18) was expressed at low levels in TNBC, and PCAT18 could sponge miR-103a-3p and promote activating transcription factor 7 expression, resulting in prevention of TNBC metastasis.
[Bioengineered]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer

Scientists explored sulfated glycosaminoglycan (sGAG) levels as a predictor of TNBC response to platinum therapy. sGAG levels were quantified in three distinct TNBC tumor models including cell line-derived, patient-derived xenograft tumors, and isogenic models deficient in sGAG biosynthesis.
[Molecular Cancer therapeutics]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Addition of Immunotherapy to Chemotherapy for Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

The authors conduct a meta-analysis, showing that the addition of programmed death-1/programmed death ligand-1 (PD-L1) blockade to chemotherapy improves progression-free survival in PD-L1 positive metastatic TNBC patients, also in the intention-to-treat population.
[Critical Reviews in Oncology Hematology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Trodelvy® as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies.
[Gilead Sciences, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada

CytoDyn, Inc. announced that Health Canada authorized the emergency use of leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, for the treatment of a patient with metastatic triple-negative breast cancer.
[CytoDyn, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share